Compounds for the treatment of sexual dysfunction
AssigneePfizer Inc.
InventorsIan Dennis Harrow, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman, Stephen Charles Phillips
Life of this patent
Estimating the term…
Loading patent…
AssigneePfizer Inc.
InventorsIan Dennis Harrow, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman, Stephen Charles Phillips
Estimating the term…
Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).
An isolated and/or purified polynucleotide comprising one or more of:
Cells deposited under Accession Number NCIMB 41110.
Dependencies are inferred from the claim text.